title: Incidence of seroconversion for hepatitis C virus in chronic haemodialysis patients: a prospective study.
abstract: We conducted a prospective study in HD patients of our unit to evaluate the incidence of seroconversion for HCV in this high-risk group. Two hundred and thirty-five patients were observed during the average follow-up of 29.4 months: 183 were seronegative and 52 seropositive for anti-HCV antibodies at the start of the study. During the observation period two of 183 patients developed anti-HCV antibodies late in the study, while the other 181 patients remained seronegative throughout the observation period; anti-HCV antibodies persisted through the follow-up in the 52 HCV-positive patients at the beginning of the study. Our results showed a very low incidence of HCV seropositivity (0.44% per year) after implementation of our operative protocol including 'universal precautions' and other infection control procedures. Once infected, there is no disappearance rate of anti-HCV. The 4-RIBA results did not change during the follow-up period. Prevalence of HCV RNA by PCR technique was 41% (22 of 54) among anti-HCV-positive patients. Future investigations are warranted to clarify the exact route of transmission of HCV among HD patients and to reduce the rate of HCV transmission in this clinical setting.
authors.affiliation: Division of Nephrology and Dialysis, Lecco Hospital, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Fabrizi
authors.forename: G
authors.initials: G
authors.lastname: Lunghi
authors.forename: I
authors.initials: I
authors.lastname: Guarnori
authors.forename: L
authors.initials: L
authors.lastname: Raffaele
authors.forename: M
authors.initials: M
authors.lastname: Crepaldi
authors.forename: A
authors.initials: A
authors.lastname: Pagano
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000276:immunology* / Q000821:virology; D018937:Hepatitis C Antibodies; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D006435:Renal Dialysis; D012307:Risk Factors
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D012367:RNA, Viral